Kaiser Larry 4
Research Summary
AI-generated summary
Medicus Pharma (MDCX) Director Larry Kaiser Receives Award
What Happened
Larry Kaiser, a director of Medicus Pharma Ltd. (MDCX), was granted a derivative award of 50,000 shares/options on June 3, 2026. The Form 4 records an acquisition (code A) of 50,000 shares at $0.00 (acquired value $0). A footnote states the instrument is an option that vests quarterly in four equal installments over one year. This was an award/compensation-style grant, not an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-03; filing date: 2026-06-04 (timely filing).
- Reported consideration: 50,000 shares/options @ $0.00 (acquired $0); transaction code A (grant/award).
- Vesting: Option vests quarterly in four equal installments over one year (per footnote F1).
- Shares owned after transaction: Not specified in this Form 4.
- Footnote: F1 confirms the award is an option with the stated vesting schedule.
- Filing timeliness: No late filing indicated.
Context
This is a compensatory derivative grant (an option award) that vests over time. Such grants do not represent an immediate purchase or sale of stock; any future value to the insider depends on the option's exercise price and the company's future share price. The Form 4 does not disclose an exercise price or post-transaction beneficial ownership in this filing.